Loading
II
Icad Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Brown Dana R, was filed 04 Apr 2023.
Icad Inc: what insiders have been doing
Icad Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Icad Inc. The previous disclosure was published on 17 July 2025.
The full history, which starts in 2016, counts 11 purchases against 23 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
162
Thresholds
n/a
Buy Volume
€551,973
11 ops. · all time
Sell Volume
€2M
23 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$16.9M
Gross profitUS$14.3M85% margin
Net income-US$4.8M-28.6% margin
Last declaration on 17 July 2025
Declarations162 total
188,725 sharesCommon StockSEC:0001193805-25-001055:0
8,488 sharesCommon StockSEC:0001193805-25-001053:0
4,134 sharesCommon StockSEC:0001193805-25-001054:0
54,350 sharesCommon StockSEC:0001193805-25-001052:0
62,217 sharesCommon StockSEC:0001193805-25-001051:0
1,198,382 sharesCommon StockSEC:0001193805-25-001050:0
52 sharesCommon StockSEC:0001193805-25-001049:0
11,483 shares0Common StockSEC:0001193805-25-000515:0
7,345 shares0Common StockSEC:0001193805-25-000514:0
15,833 shares0Common StockSEC:0001193805-25-000246:0
25,833 shares0Common StockSEC:0001193805-25-000247:0
40,000 shares@ US$1.30100.0% of flowCommon StockSEC:0000899243-23-010416:0
Canonical exit: 29 Jun 2023 (T+90)
45,000 shares@ US$2.2755.2% of flowCommon StockSEC:0000899243-22-031032:0
20,000 shares@ US$5.7537.1% of flowCommon StockSEC:0000899243-22-011245:0
5,500 shares@ US$4.63100.0% of flowCommon StockSEC:0000899243-22-008993:0
Canonical exit: 1 Jun 2022 (T+90)
10,000 shares@ US$5.2610.4% of flowCommon StockSEC:0000899243-22-005408:0
10,000 shares@ US$6.2012.5% of flowCommon StockSEC:0000899243-22-001551:0
17,006 shares@ US$6.1744.7% of flowCommon StockSEC:0000899243-22-000861:0
Canonical exit: 5 Apr 2022 (T+90)
7,000 shares@ US$7.05100.0% of flowCommon StockSEC:0000899243-21-048350:0
Canonical exit: 8 Mar 2022 (T+90)
6,900 shares@ US$7.24100.0% of flowCommon StockSEC:0000899243-21-047684:0
Canonical exit: 9 Mar 2022 (T+90)
13,475 shares@ US$7.38100.0% of flowCommon StockSEC:0000899243-21-047475:0
Canonical exit: 8 Mar 2022 (T+90)
1,500 shares@ US$7.31100.0% of flowCommon StockSEC:0000899243-21-047477:0
Canonical exit: 8 Mar 2022 (T+90)
10,000 shares@ US$6.7113.5% of flowCommon StockSEC:0000899243-21-047335:0
10,000 shares@ US$10.8921.4% of flowCommon StockSEC:0000899243-21-043947:0
30,000 shares@ US$3.1544.8% of flowCommon StockSEC:0000899243-21-043954:0
25 of 162 declarations
About Icad Inc
iCAD Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States. Headquartered in Nashua, New Hampshire, the company has historically focused on technologies used for the early detection and treatment of cancer, with a particularly strong emphasis on breast health. Its profile is that of a specialized, technology-driven medtech company rather than a broad-based healthcare supplier.
iCAD’s core business is centered on its ProFound Breast Health Suite, which includes AI-enabled mammography reading support, cancer detection software, short-term breast cancer risk assessment tools, and more recent capabilities related to breast density and breast arterial calcification assessment. The company has also been associated with its Xoft radiation therapy platform, including electronic brachytherapy and intraoperative radiation therapy solutions, although its strategic messaging in recent years has increasingly concentrated on breast imaging and artificial intelligence. In recent disclosures, iCAD has described itself as providing clinically proven AI-powered breast health solutions.
Read moreShow less
From a historical standpoint, iCAD was originally founded in 1984 as Howtek, Inc., and later adopted the iCAD name in 2002. Its corporate headquarters are in Nashua, New Hampshire, reinforcing its operational base in the United States. The company has maintained an international footprint through distributors, commercial partners and a French subsidiary, but its primary commercial exposure remains in North America, serving imaging centers, radiology groups and mammography providers.
In competitive terms, iCAD operates in a focused segment of the health-tech market where differentiation depends on clinical performance, workflow integration and peer-reviewed evidence. It competes with imaging software vendors, radiology AI specialists and larger medical device groups. iCAD’s main advantage has been its narrow focus on breast cancer detection and its ability to embed AI into the screening workflow.
A major recent development was RadNet’s April 2025 announcement that its DeepHealth subsidiary would acquire iCAD. Subsequent communications indicated shareholder approval efforts and ongoing commercial momentum for ProFound AI, including a partnership with RamSoft. For French-speaking investors, iCAD is therefore best viewed as a NASDAQ-listed U.S. health-tech name whose near-term story is now dominated by its integration into the DeepHealth/RadNet ecosystem.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
